Immupharma Plc (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the completion of the Lupuzor™ pivotal phase III study and an initiation of a follow up study. Tim explains the significance of the announcement, confidence in delivering top line results in Q1, why the follow up study is being initiated, the importance of the safety profile and the next key milestone.
Commenting on the trial update, Robert Zimmer (MD, PhD), President & CSO said: “We are delighted to announce this major milestone for ImmuPharma Plc in having completed on track this pivotal Phase III trial for Lupuzor™.
“I would like to take this opportunity of thanking all of our Clinical Investigators; Simbec-Orion, our clinical research organisation and the ImmuPharma France team led by Dr Fanny Valleix, Head of Clinical Research. All were paramount in the execution and completion of this trial.
“With the continued robust safety achieved over this trial, we look forward with continued confidence to reporting top line results of the study this Q1 2018.”